Structure-guided optimization of 1H-imidazole-2-carboxylic acid derivatives affording potent VIM-Type metallo-β-lactamase inhibitors
- PMID: 34763944
- DOI: 10.1016/j.ejmech.2021.113965
Structure-guided optimization of 1H-imidazole-2-carboxylic acid derivatives affording potent VIM-Type metallo-β-lactamase inhibitors
Abstract
Production of metallo-β-lactamases (MBLs) in bacterial pathogens is an important cause of resistance to the 'last-resort' carbapenem antibiotics. Development of effective MBL inhibitors to reverse carbapenem resistance in Gram-negative bacteria is still needed. We herein report X-ray structure-guided optimization of 1H-imidazole-2-carboxylic acid (ICA) derivatives by considering how to engage with the active-site flexible loops and improve penetration into Gram-negative bacteria. Structure-activity relationship studies revealed the importance of appropriate substituents at ICA 1-position to achieve potent inhibition to class B1 MBLs, particularly the Verona Integron-encoded MBLs (VIMs), mainly by involving ingenious interactions with the flexible active site loops as observed by crystallographic analyses. Of the tested ICA inhibitors, 55 displayed potent synergistic antibacterial activity with meropenem against engineered Escherichia coli strains and even intractable clinically isolated Pseudomonas aeruginosa producing VIM-2 MBL. The morphologic and internal structural changes of bacterial cells after treatment further demonstrated that 55 crossed the outer membrane and reversed the activity of meropenem. Moreover, 55 showed good pharmacokinetic and safety profile in vivo, which could be a potential candidate for combating VIM-mediated Gram-negative carbapenem resistance.
Keywords: 1H-imidazole-2-carboxylic acid derivatives; Anchor pharmacophore; Carbapenem resistance; Metallo-β-lactamase; Pseudomonas aeruginosa; Structure-guided optimization.
Copyright © 2021 Elsevier Masson SAS. All rights reserved.
Conflict of interest statement
Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Similar articles
-
Sulfamoyl Heteroarylcarboxylic Acids as Promising Metallo-β-Lactamase Inhibitors for Controlling Bacterial Carbapenem Resistance.mBio. 2020 Mar 17;11(2):e03144-19. doi: 10.1128/mBio.03144-19. mBio. 2020. PMID: 32184250 Free PMC article.
-
Design, Synthesis, and Biological Evaluation of New 1H-Imidazole-2-Carboxylic Acid Derivatives as Metallo-β-Lactamase Inhibitors.Bioorg Med Chem. 2022 Oct 15;72:116993. doi: 10.1016/j.bmc.2022.116993. Epub 2022 Sep 5. Bioorg Med Chem. 2022. PMID: 36084491
-
H2dpa derivatives containing pentadentate ligands: An acyclic adjuvant potentiates meropenem activity in vitro and in vivo against metallo-β-lactamase-producing Enterobacterales.Eur J Med Chem. 2021 Nov 15;224:113702. doi: 10.1016/j.ejmech.2021.113702. Epub 2021 Jul 13. Eur J Med Chem. 2021. PMID: 34303873
-
Diversity and Proliferation of Metallo-β-Lactamases: a Clarion Call for Clinically Effective Metallo-β-Lactamase Inhibitors.Appl Environ Microbiol. 2018 Aug 31;84(18):e00698-18. doi: 10.1128/AEM.00698-18. Print 2018 Sep 15. Appl Environ Microbiol. 2018. PMID: 30006399 Free PMC article. Review.
-
Designing Inhibitors of β-Lactamase Enzymes to Overcome Carbapenem Resistance in Gram-Negative Bacteria.Acc Chem Res. 2021 May 4;54(9):2055-2064. doi: 10.1021/acs.accounts.0c00863. Epub 2021 Mar 31. Acc Chem Res. 2021. PMID: 33788541 Review.
Cited by
-
Recent Developments to Cope the Antibacterial Resistance via β-Lactamase Inhibition.Molecules. 2022 Jun 14;27(12):3832. doi: 10.3390/molecules27123832. Molecules. 2022. PMID: 35744953 Free PMC article. Review.
-
Navigating the complexities of drug development for metallo-β-lactamase inhibitors.RSC Med Chem. 2025 May 27. doi: 10.1039/d5md00035a. Online ahead of print. RSC Med Chem. 2025. PMID: 40521342 Free PMC article. Review.
-
Breakthrough Advances in Beta-Lactamase Inhibitors: New Synthesized Compounds and Mechanisms of Action Against Drug-Resistant Bacteria.Pharmaceuticals (Basel). 2025 Feb 3;18(2):206. doi: 10.3390/ph18020206. Pharmaceuticals (Basel). 2025. PMID: 40006020 Free PMC article. Review.
-
Small-molecule inhibitors of bacterial-producing metallo-β-lactamases: insights into their resistance mechanisms and biochemical analyses of their activities.RSC Med Chem. 2023 Mar 31;14(6):1012-1048. doi: 10.1039/d3md00036b. eCollection 2023 Jun 22. RSC Med Chem. 2023. PMID: 37360393 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous